Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Omicron XBB 1.5

- PMLiVE

MHRA approves Bavarian Nordic’s chikungunya vaccine Vimkunya

Approximately 620,000 cases of the mosquito-borne viral disease were reported worldwide in 2024

EU flag

CHMP recommends Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

Approximately 480,000 cases of the mosquito-borne viral disease were reported globally in 2024

EU flag

EC approves Bavarian Nordic’s mpox vaccine Imvanex for use in adolescents

More than 120 countries have confirmed over 103,000 cases of mpox since the global outbreak began in 2022

- PMLiVE

Moderna’s JN.1-adapted COVID-19 vaccine approved by MHRA for adults and children

The JCVI has already advised the UK government on eligible groups for this year’s autumn vaccination programme

- PMLiVE

Novavax’s JN.1-adapted COVID-19 vaccine granted FDA emergency use authorisation

JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants

- PMLiVE

FDA approves updated COVID-19 vaccines to better protect against current variants

Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

- PMLiVE

JCVI announces advice for autumn COVID-19 vaccination programme eligibility

The Committee has advised offering the vaccine to those at high risk of serious disease

- PMLiVE

Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine recommended by CHMP

The vaccine generated an improved response against several Omicron JN.1 sublineages

- PMLiVE

AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients

Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths

- PMLiVE

Study reveals third COVID-19 vaccine dose improves defence in vulnerable patients

Approximately 90% of patients who received a third dose developed significant levels of antibodies

- PMLiVE

Sanofi and Novavax announce COVID-19 vaccine licensing agreement worth over $1.2bn

The deal gives Sanofi a licence to use Novavax’s COVID-19 vaccine in combination with its own flu vaccines

- PMLiVE

Researchers’ new vaccine technology shows efficacy against broad range of coronaviruses

The vaccine provided protection against coronaviruses that have not yet emerged

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links